- Home
- OSUR vs NTHI Comparison
OSUR vs NTHI Comparison
Compare OSUR & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- NTHI
- Stock Information
- Founded
- OSUR 2000
- NTHI 2008
- Country
- OSUR United States
- NTHI United States
- Employees
- OSUR N/A
- NTHI N/A
- Industry
- OSUR Medical/Dental Instruments
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- NTHI Health Care
- Exchange
- OSUR Nasdaq
- NTHI Nasdaq
- Market Cap
- OSUR 260.3M
- NTHI 225.0M
- IPO Year
- OSUR 1986
- NTHI N/A
- Fundamental
- Price
- OSUR $3.32
- NTHI $11.26
- Analyst Decision
- OSUR Hold
- NTHI
- Analyst Count
- OSUR 2
- NTHI 0
- Target Price
- OSUR $5.50
- NTHI N/A
- AVG Volume (30 Days)
- OSUR 720.7K
- NTHI 56.0K
- Earning Date
- OSUR 05-07-2025
- NTHI 01-01-0001
- Dividend Yield
- OSUR N/A
- NTHI N/A
- EPS Growth
- OSUR N/A
- NTHI N/A
- EPS
- OSUR N/A
- NTHI N/A
- Revenue
- OSUR $185,827,000.00
- NTHI $83,000.00
- Revenue This Year
- OSUR N/A
- NTHI N/A
- Revenue Next Year
- OSUR $7.46
- NTHI N/A
- P/E Ratio
- OSUR N/A
- NTHI N/A
- Revenue Growth
- OSUR N/A
- NTHI N/A
- 52 Week Low
- OSUR $2.69
- NTHI N/A
- 52 Week High
- OSUR $6.35
- NTHI N/A
- Technical
- Relative Strength Index (RSI)
- OSUR 43.07
- NTHI N/A
- Support Level
- OSUR $3.34
- NTHI N/A
- Resistance Level
- OSUR $3.56
- NTHI N/A
- Average True Range (ATR)
- OSUR 0.16
- NTHI 0.00
- MACD
- OSUR -0.00
- NTHI 0.00
- Stochastic Oscillator
- OSUR 2.17
- NTHI 0.00
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.